This demonstrates that CD19‐81‐293‐EXO is highly effective at eradicating malignant B‐ALL cells, indicating its potential as a novel cell therapy strategy for treating B‐ALL. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.